论文部分内容阅读
目的:探讨三通输液连接器在卵巢癌腹腔积液患者应用HGGZ-102型体腔热灌注机行腹腔热灌注过程中对温度调控的作用。方法:以2013年4月-2014年9月收治的未使用三通输液连接器的HGGZ-102型体腔热灌注机进行腹腔热灌注治疗的39例卵巢癌腹腔积液患者作为对照组:2014年10月-2015年5月收治的使用三通输液连接器的HGGZ-102型体腔热灌注机行腹腔热灌注治疗的45例卵巢癌腹腔积液患者作为研究组,2组患者均采用TP方案(紫杉醇联合顺铂)进行化疗(紫杉醇静脉滴注d 1,顺铂腹腔热灌注d 1和d 8),每3周重复1次共进行6个周期的治疗。比较热灌注时2组灌注药物进入腹腔和抽出腹腔时的温度及疗效。结果:研究组患者3个循环药物进入腹腔的温度阈值均精准控制在43.5~44.5℃,抽出腹腔时的最高温度均接近或达到目标温度阈39.5~40.5℃;研究组患者腹腔积液治疗有效率为71.1%,对照组为46.2%,2组间比较差异有统计学意义(P<0.05);2组患者不良反应的发生率,则差异无统计学意义(P>0.05)。结论:使用三通输液连接器进行卵巢癌腹腔积液患者的腹腔热灌注治疗,可以达到精准控温,提高热灌注化疗药物疗效及安全性的作用。
OBJECTIVE: To investigate the effect of three-way infusion connector on temperature regulation during peritoneal hyperthermic perfusion by using HGGZ-102 cavity thermal perfusion machine in patients with ascites of ovarian cancer. METHODS: Thirty-nine patients with peritoneal effusion undergoing intraperitoneal hyperthermic perfusion of HGGZ-102 body cavity thermofusion machine without the use of three-way infusion connector, which were treated from April 2013 to September 2014, were selected as the control group: 2014 45 cases of patients with ascites from patients with ovarian cancer treated with intraperitoneal hyperthermic perfusion were treated with HGGZ-102 type of body cavity thermoformer with three-way infusion connector in October-May 2015. The two groups were treated with TP regimen Paclitaxel plus cisplatin) (paclitaxel intravenous infusion of d 1, intraperitoneal hot cisplatin d 1 and d 8), repeated once every 3 weeks for a total of 6 cycles of treatment. Compare the temperature and curative effect when two groups of perfusion drugs enter the abdominal cavity and pull out the abdominal cavity during the hot perfusion. Results: The temperature thresholds of three circulating drugs entering the peritoneal cavity of patients in the study group were controlled accurately at 43.5-44.5 ° C, and the maximum temperature at the time of abdominal cavity extraction was close to or reached the target temperature threshold of 39.5-40.5 ° C. The study group had an effective rate of peritoneal effusion treatment (71.1%) and control group (46.2%). The difference between the two groups was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: The intraperitoneal hyperthermic perfusion in patients with ascites due to ovarian cancer can achieve precise temperature control by using the three-way infusion connector, and can improve the curative effect and safety of hot-perfusion chemotherapy drugs.